- World rank, all time
- #24,357 of 42,892
- Rank in United States
- #5,229 of 8,685
- Research works
- 154 ▼ 33% vs 2013–17
- Citations
- 4.2k 27.0 per fractional work
- Top-10% rate
- 8.6% record average 16.5%
- Open access
- 44% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Mathematics, 6.8×. Every wedge is a field page.
- Mathematics 6.8×
- Pharmacology, Toxicology and Pharmaceutics 5.2×
- Economics, Econometrics and Finance 4.5×
- Neuroscience 2.4×
- Medicine 2.3×
- Biochemistry, Genetics and Molecular Biology 2.2×
- Health Professions 1.4×
- Psychology 1.0×
- Computer Science 1.0×
- Decision Sciences 0.9×
- Dentistry 0.3×
- Immunology and Microbiology 0.3×
- Arts and Humanities 0.2×
- Environmental Science 0.2×
- Social Sciences 0.1×
- Chemistry 0.1×
- Materials Science 0.1×
- Engineering 0.1×
Who are the top researchers at TetraLogic Pharmaceuticals (United States)?
Ranked on the composite score, Suzanne Hendrix lead among researchers whose main affiliation is TetraLogic Pharmaceuticals (United States).
- 1 Suzanne Hendrix United States · #1,376,900 worldwide 20 citations · 36 works
Which keywords describe research at TetraLogic Pharmaceuticals (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Alzheimer's Disease, Biomarkers, Oxidative Stress, Neurodegeneration, Aging, Neuroimaging, Cognitive Training and Dementia.
- Epidemiology
- Propensity Score
- Causal Inference
- Cholinesterase Inhibitors
- a-Synuclein
- Toxicology
- Diagnostic Criteria
- False Discovery Rate
- Virtual Screening
- Medicinal Chemistry
- Phosphoethanolamine
- Cancer
- Machine Learning
- Cost-effectiveness Analysis
- Tau Pathology
- Amyloid Hypothesis
- Mild Cognitive Impairment
- Cognitive Training
- Neurodegeneration
- Biomarkers
- Alzheimer's Disease
- Oxidative Stress
- Aging
- Dementia
- Neuroimaging
- Neuroinflammation
- Quality of Life
- Health Utility Measures
- Metabolic Syndrome
- Mitochondrial Dysfunction
- Synthetic
- Molecular Docking
- Adaptive Designs
- Parkinson's Disease
- Neurodegenerative Diseases
- Dopaminergic Neurons
- Acetylcholinesterase
- Clinical Trials
- Community Engagement
- Depression
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Alzheimer's Disease10▲ 76×6 topics
- Biomarkers8▲ 26×6 topics
- Oxidative Stress7▲ 9.8×11 topics
- Neurodegeneration7▲ 52×4 topics
- Aging6▲ 25×7 topics
- Cognitive Training5▲ 130×2 topics
- Dementia5▲ 127×1 topic
- Mild Cognitive Impairment5▲ 142×1 topic
- Neuroimaging5▲ 44×3 topics
- Amyloid Hypothesis5▲ 185×1 topic
- Neuroinflammation5▲ 39×2 topics
- Tau Pathology5▲ 185×1 topic
- Quality of Life5▲ 7.2×5 topics
- Cost-effectiveness Analysis4▲ 97×1 topic
- Health Utility Measures4▲ 97×1 topic
- Machine Learning3▲ 2.1×4 topics
- Metabolic Syndrome3▲ 7.5×4 topics
- Cancer3▲ 4.3×2 topics
- Mitochondrial Dysfunction3▲ 20×5 topics
- Phosphoethanolamine3▲ 494×1 topic
- Synthetic3▲ 494×1 topic
- Medicinal Chemistry2▲ 18×2 topics
- Molecular Docking2▲ 38×1 topic
- Virtual Screening2▲ 52×1 topic
- Adaptive Designs2▲ 223×1 topic
- False Discovery Rate2▲ 223×1 topic
- Parkinson's Disease2▲ 19×4 topics
- Diagnostic Criteria2▲ 17×2 topics
- Neurodegenerative Diseases2▲ 23×3 topics
- Toxicology2▲ 22×2 topics
- Dopaminergic Neurons2▲ 54×1 topic
- a-Synuclein2▲ 66×1 topic
- Acetylcholinesterase2▲ 151×1 topic
- Cholinesterase Inhibitors2▲ 151×1 topic
- Clinical Trials2▲ 4.9×4 topics
- Causal Inference1▲ 84×1 topic
- Community Engagement1▲ 7.8×2 topics
- Propensity Score1▲ 153×1 topic
- Depression1▲ 2.7×5 topics
- Epidemiology1▼ 0.61×7 topics
Which research topics does TetraLogic Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Health Systems, Economic Evaluations, Quality of Life and Biological Research and Disease Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Dementia and Cognitive Impairment Research Psychiatry and Mental health 5 works
- 2 Alzheimer's disease research and treatments Physiology 5 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 4 works
- 4 Biological Research and Disease Studies Molecular Biology 3 works
- 5 Computational Drug Discovery Methods Computational Theory and Mathematics 2 works
- 6 Statistical Methods in Clinical Trials Statistics and Probability 2 works
- 7 Parkinson's Disease Mechanisms and Treatments Neurology 2 works
- 8 Cholinesterase and Neurodegenerative Diseases Pharmacology 2 works
- 9 Advanced Causal Inference Techniques Statistics and Probability 1 works
- 10 Genetic Neurodegenerative Diseases Cellular and Molecular Neuroscience 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has TetraLogic Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 33% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Malvern
- Siemens Healthcare (United States)
- Endo Pharmaceuticals (United States)
- Immaculata University
- Ricoh (United States)
- Reaction Biology Corporation (United States)
- Applied Pulsed Power (United States)
- Saint-Gobain (United States)
- BioTelemetry (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.